Endoscopic variceal ligation-induced ulcer bleeding: a retrospective analysis of endoscopic therapy and patient outcomes

Aims Endoscopic variceal ligation (EVL)-induced ulcer bleeding is a rare complication, occurring in 2% – 8% of cases, but is potentially life-threatening with mortality rates ranging from 20% to 63%. Limited data exist regarding the efficacy and outcomes of the available endoscopic treatment options for this complication. Therefore, we evaluated their primary hemostasis success rate and 5-day bleeding recurrence rate as well as the in-hospital mortality rate.

Methods This retrospective study analysed all EVL procedures performed at the Charité University Clinics, Campus Virchow and Campus Mitte, in Berlin from 01.01.2016 until 30.06.2023. A total of 1864 EVLs were conducted; with 73,4% performed electively, 9,5% semi-electively during inpatient treatment for decompensated liver cirrhosis and 17,1% performed emergently due to esophageal variceal bleeding. Ulcer bleeding as a complication of EVL was observed in 61 cases (3,3%), one case was excluded due to missing data.

Results EVL-induced ulcer bleeding was a rare event after elective EVL (0,44%). However, the relative risk of this complication increased 20-fold and 37-fold after emergent or semi-elective EVL. The most commonly employed endoscopic therapy was a repeat EVL (n=24, 40%), either alone or in combination with other endoscopic modalities. This approach achieved a primary hemostasis rate of 83,3% but had a 30% 5-day bleeding recurrence rate. Fibrin glue injection was the second most often used therapy (n=16, 26,7%), either alone or in combination with other modalities. The primary hemostasis rate was 87,5% and the 5-day bleeding recurrence rate was 31,5%. Other less frequently used treatments were: no intervention, Sengstaken-Blakemore tube, epinephrine injection, fully covered self-expandable metallic stent, synthetic peptides, cyanoacrylate and clips. Primary hemostasis was achieved in 45% of these patients with one endoscopic method, whereas for 26,7% of the patients a combination of 2-4 methods was required. The in-hospital mortality for this cohort was 46,7%. Univariate analysis showed that the MELD (Model for End-stage Liver Disease) score and the CLIF-C acute decompensation score, as well as the presence of organ failure or acute on chronic liver failure at the time of the EVL along with bleeding recurrence or hospital-acquired infection were associated with increased in-hospital mortality. Based on multivariate analysis, bleeding recurrence was the strongest predictor of in-hospital mortality (OR=12,78; 95%-CI 1,43 – 114,34; p=0,02). Although the small sample size limited definitive conclusions, no endoscopic treatment demonstrated superiority regarding 5-day bleeding recurrence or in-hospital mortality.

Conclusions EVL-induced ulcer bleeding occurs more frequently following semi-elective or emergent EVLs, with multiple interventions demonstrating similar hemostasis rates. However, the risk of re-bleeding remains substantial and serves as a strong, independent predictor of mortality. Large multicenter studies are essential to develop tailored treatment algorithms.

 

Scroll to top

Conflicts of Interest

Authors do not have any conflict of interest to disclose.

Publication History

Article published online:
27 March 2025